
Thesis proposal

Nil Adell Mill

Winter 2020

Institute of Neuroinformatics

1 Introduction/Background

2 Drug discovery—the process by which a potential new medicine is identified—is a complex process that
3 encompasses the intersection of several fields (such as biology, statistics, chemistry or pharmacology). The
4 entire process is a long and costly endeavor, with a typical time-frame of 10 to 20 years till market release
5 and an estimated cost between 2 and 3 billion USD [Schneider, 2019, Scannell et al., 2012]. With just a small
6 quantity of the initially identified compounds actually becoming an approved medicine—only 1 out of 10 000
7 synthesized molecules gets market approval one day. Many of these dropouts happening at the early stages of
8 the entire pipeline.

9 It exists, then, a need for better mechanisms for detecting better candidates. One of the most promising direc-
10 tions is to improve the *in-silico* methods—computational simulations are relatively cheap and quick run that
11 makes them an interesting solution. *In-silico* simulations then cover two main aspects: **predictive modelling**,
12 meaning modeling the dynamics of the human body—such that any effect relevant to the drug or the disease will
13 be captured by it—and **generative modelling**, i.e. methods to generate good candidates which, in part, means
14 methods that are effective at exploring the vast space of possible compounds, estimated to be on the order of
15 10^{60} [Reymond et al., 2012]. Several computational approaches have been used over the years, from modeling
16 molecular dynamics simulations to data-driven statistical methods [Hung and Chen, 2014, Kuhn et al., 2016].
17 Recently deep learning (DL) has shown signs to be a potential game-changer [Dargan et al., 2019].

18 DL has been able to capitalize on the exponential growth of data and the higher availability of computational
19 resources. DL has had remarkable success in computer vision (CV) [Guo et al., 2016] and natural language
20 processing (NLP) [Young et al., 2018], and has become the go-to solution for any problem in these two fields.
21 For instance, in the case of CV, where we deal with images, a key element of any architecture’s success
22 was the use of convolutional layers—one will mostly observe convolutional neural networks (CNNs) when
23 analyzing the state of the art in CV—which introduces a structural prior based on the structure of the
24 data [Fukushima, 1980, LeCun, 1989, Ulyanov D., Vedaldi A., 2018]. A similar case can be made for NLP.
25 When we deal with biological and molecular data, it exists a challenge and an opportunity on how to deal
26 with this intrinsic structure, i.e. leveraging the knowledge that they are graphs. Efforts in generalizing the
27 convolution operator on non-euclidian structures have [given rise to the appearance of] graph convolutional
28 neural networks (GCNNs) [Wu et al., 2019]. GCNNs, at the same time, started penetrating the field of drug
29 discovery [Sun et al., 2019].

30 Another of the big challenges is to unify all the aspects of drug-discovery and be able to incorporate all the
31 relevant biological information when designing possible candidate molecules. An initial success story on that
32 line is a recent paper [Zavoronkov et al., 2019] where the authors describe a deep learning method by which
33 they are able to discover, synthesize, and test in an animal model, inhibitors of discoidin domain receptor 1
34 (DDR1)—a kinase implicated in fibrosis—in less than two months.

35 Those promising results, albeit encouraging, are just the tip of the iceberg. There is still a long way until
36 a model can satisfactorily capture the biological complexity of an arbitrary target and produce promising
37 candidates. On top of that, there is an added dimension, as such model should account for the variability from
38 patient to patient and be able to generate a molecule that accommodates for all the genotypic and phenotypic
39 variants or generate different candidates for each of the genetic populations of interest. That is especially
40 important for hypercomplex diseases; for example in cancer where a genotypically heterogeneous cancer
41 population may appear within a single patient [Boland and Yurgelun, 2017]. So the same variant effects arise

inside a dynamic ecosystem, where a drug that just targets a subpopulation may lead to an evolutionary pressure complicating further the treatment outlook [Enriquez-Navas et al., 2015].

There is then a great need to develop models that can be conditioned based on a large set of biological factors and meaningfully account for these variations when generating a compound or/and evaluating a compound's effect when administered. What is, in other words, the need for the wider adoption of precision medicine.

Last of all, in a more holistic view, it is of interest to develop multi-scale models that capture system complexity at different levels. For instance, a model that can learn protein-compound interactions—commonly known as the docking problem—while at the same time use this information to predict effects of the introduction of the compound on the larger protein-protein interaction (PPI) network [Sun et al., 2019].

Aim & Methods

The aim of this thesis will be two-fold. On the one side, analyze how the explicit use of GCNNs may open new opportunities when dealing with biological and chemical data. On the other side, explore how modeling the biology at different levels (e.g. molecular structure v.s. molecular interaction network) may help create better models. Furthermore, evaluate how these different scales may be integrated.

This precise work will be focused on exploring all these concepts in the context of designing anti-cancer drugs. The work will be done in collaboration with the Computational Systems Biology group at IBM Research (Zurich), which is currently focused on individualized pediatric cure (iPC). As such, an end goal of this project is for the end results of it to help in that effort, for instance in contributing to the ongoing research in neuroblastoma.

As mentioned previously, the idea of using GCNNs for drug discovery is not a new one in the literature [Sun et al., 2019]. My project will build upon those ideas presented in the literature, expand them and test their feasibility by implementing them into a wider framework for drug design [Born et al., 2019]. In that context, two main areas of application appear. One of them is to re-design the generative model, for instance by reframing the variational autoencoders, used for molecule generation, to architectures that operate over graphs [Simonovsky and Komodakis, 2018, Li et al., 2018a, Li et al., 2018b]. The second area is to find better ways to assess the activity of these molecules, and in a wider context, assess their relevance as drug candidates, i.e. improve the predictive model. In the concrete case of the mentioned framework, it is done by using a critic network [Manica et al., 2019]. This can be expanded on a set of different fronts: using structural data instead of SMILES¹ [Li et al., 2017, Do et al., 2019], by using GCNNs over PPI networks, like STRING², in a manner that allows for the use all the information available [Oskooei et al., 2019, Wang et al., 2019], or by introducing particular scores (rewards) based in the interaction of the compound to certain targets [Yingkai Gao et al., 2018, Zhavoronkov et al., 2019] or the combination of the compound with other drugs [Zitnik et al., 2018]—a common practice in patients with cancer. All these possible changes on the critic model would apply at different abstraction levels. That opens the door to seek for ways to integrate the representations learnt at those different stages [Ying et al., 2018, Ma and Zhang, 2019, Huang et al., 2019]. On top of that information extracted from here could be then leveraged on the drug generation part of the framework.

References

- [Boland and Yurgelun, 2017] Boland, C. R. and Yurgelun, M. B. (2017). Mutational cascades in cancer.
- [Born et al., 2019] Born, J., Manica, M., Oskooei, A., Cadow, J., and Martínez, M. R. (2019). PaccMann^{RL}: Designing anticancer drugs from transcriptomic data via reinforcement learning.
- [Dargan et al., 2019] Dargan, S., Kumar, M., Ayyagari, M. R., and Kumar, G. (2019). A Survey of Deep Learning and Its Applications: A New Paradigm to Machine Learning. *Archives of Computational Methods in Engineering*.
- [Do et al., 2019] Do, K., Tran, T., and Venkatesh, S. (2019). Graph transformation policy network for chemical reaction prediction. In *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, pages 750–760.

¹<http://opensmiles.org/>

²<https://string-db.org/>

89 [Enriquez-Navas et al., 2015] Enriquez-Navas, P. M., Wojtkowiak, J. W., and Gatenby, R. A. (2015). Appli-
90 cation of evolutionary principles to cancer therapy.

91 [Fukushima, 1980] Fukushima, K. (1980). Neocognitron: A self-organizing neural network model for a
92 mechanism of pattern recognition unaffected by shift in position. *Biological Cybernetics*, 36(4):193–202.

93 [Guo et al., 2016] Guo, Y., Liu, Y., Oerlemans, A., Lao, S., Wu, S., and Lew, M. S. (2016). Deep learning for
94 visual understanding: A review. *Neurocomputing*, 187:27–48.

95 [Huang et al., 2019] Huang, J., Li, Z., Li, N., Liu, S., and Li, G. (2019). AttPool: Towards Hierarchical
96 Feature Representation in Graph Convolutional Networks via Attention Mechanism. *The IEEE International
97 Conference on Computer Vision (ICCV)*, pages 6480–6489.

98 [Hung and Chen, 2014] Hung, C. L. and Chen, C. C. (2014). Computational approaches for drug discovery.

99 [Kuhn et al., 2016] Kuhn, M., Yates, P., and Hyde, C. (2016). Statistical Methods for Drug Discovery. pages
100 53–81.

101 [LeCun, 1989] LeCun, Y. (1989). Generalization and network design strategies. Technical report.

102 [Li et al., 2017] Li, J., Cai, D., and He, X. (2017). Learning Graph-Level Representation for Drug Discovery.
103 Technical report.

104 [Li et al., 2018a] Li, Y., Vinyals, O., Dyer, C., Pascanu, R., and Battaglia, P. (2018a). Learning Deep
105 Generative Models of Graphs.

106 [Li et al., 2018b] Li, Y., Zhang, L., and Liu, Z. (2018b). Multi-objective de novo drug design with conditional
107 graph generative model. *Journal of Cheminformatics*, 10(1).

108 [Ma and Zhang, 2019] Ma, T. and Zhang, A. (2019). Incorporating Biological Knowledge with Factor Graph
109 Neural Network for Interpretable Deep Learning.

110 [Manica et al., 2019] Manica, M., Oskooei, A., Born, J., Subramanian, V., Saéz-Rodríguez, J., and Rodríguez
111 Martínez, M. (2019). Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal
112 Attention-Based Convolutional Encoders. Technical report.

113 [Oskooei et al., 2019] Oskooei, A., Manica, M., Mathis, R., and Martínez, M. R. (2019). Network-based
114 Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identifi-
115 cation in Cancer. *Scientific Reports*, 9(1).

116 [Reymond et al., 2012] Reymond, J. L., Ruddigkeit, L., Blum, L., and van Deursen, R. (2012). The enumera-
117 tion of chemical space. *Wiley Interdisciplinary Reviews: Computational Molecular Science*, 2(5):717–733.

118 [Scannell et al., 2012] Scannell, J. W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the
119 decline in pharmaceutical R&D efficiency. Technical Report 3.

120 [Schneider, 2019] Schneider, G. (2019). Mind and machine in drug design. *Nature Machine Intelligence*,
121 1(3):128–130.

122 [Simonovsky and Komodakis, 2018] Simonovsky, M. and Komodakis, N. (2018). GraphVAE: Towards
123 generation of small graphs using variational autoencoders. In *Lecture Notes in Computer Science (including
124 subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)*, volume 11139
125 LNCS, pages 412–422.

126 [Sun et al., 2019] Sun, M., Zhao, S., Gilvary, C., Elemento, O., Zhou, J., and Wang, F. (2019). Graph
127 convolutional networks for computational drug development and discovery. *Briefings in Bioinformatics*,
128 2019(0):1–17.

129 [Ulyanov D., Vedaldi A., 2018] Ulyanov D., Vedaldi A., L. V. (2018). Deep Image Prior. Technical report.

130 [Wang et al., 2019] Wang, M., Yu, L., Zheng, D., Gan, Q., Gai, Y., Ye, Z., Li, M., Zhou, J., Huang, Q., Ma,
131 C., Huang, Z., Guo, Q., Zhang, H., Lin, H., Zhao, J., Li, J., Smola, A., and Zhang, Z. (2019). Deep Graph
132 Library: Towards Efficient and Scalable Deep Learning on Graphs. Technical report.

133 [Wu et al., 2019] Wu, Z., Pan, S., Chen, F., Long, G., Zhang, C., and Yu, P. S. (2019). A Comprehensive
134 Survey on Graph Neural Networks. Technical report.

135 [Ying et al., 2018] Ying, R., Morris, C., Hamilton, W. L., You, J., Ren, X., and Leskovec, J. (2018). Hier-
136 archical graph representation learning with differentiable pooling. In *Advances in Neural Information
137 Processing Systems*, volume 2018-Decem, pages 4800–4810.

138 [Yingkai Gao et al., 2018] Yingkai Gao, K., Fokoue, A., Luo, H., Iyengar, A., Dey, S., and Zhang, P. (2018).
139 Interpretable drug target prediction using deep neural representation. In *IJCAI International Joint Confer-
140 ence on Artificial Intelligence*, volume 2018-July, pages 3371–3377.

- 141 [Young et al., 2018] Young, T., Hazarika, D., Poria, S., and Cambria, E. (2018). Recent trends in deep learning
142 based natural language processing.
- 143 [Zhavoronkov et al., 2019] Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A.,
144 Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., Volkov, Y.,
145 Zholus, A., Shayakhmetov, R. R., Zhebrak, A., Minaeva, L. I., Zagribelnyy, B. A., Lee, L. H., Soll, R.,
146 Madge, D., Xing, L., Guo, T., and Aspuru-Guzik, A. (2019). Deep learning enables rapid identification of
147 potent DDR1 kinase inhibitors. *Nature Biotechnology*, 37(9):1038–1040.
- 148 [Zitnik et al., 2018] Zitnik, M., Agrawal, M., and Leskovec, J. (2018). Modeling polypharmacy side effects
149 with graph convolutional networks. In *Bioinformatics*, volume 34, pages i457–i466.